72 Hours at API China: Where China’s API Export Industry Is Heading Next

On May 15, the 94th China International Pharmaceutical API / Intermediates / Packaging / Equipment Fair, API China 2026, successfully concluded at the National Exhibition and Convention Center in Shanghai.

Organized by Reed Sinopharm Exhibitions, the exhibition was held alongside PHARMCHINA 2026 and NHNE 2026. Covering a total exhibition area of 170,000 square meters across eight halls, the event attracted more than 3,000 pharmaceutical, healthcare, and wellness enterprises from around the world.

As one of China’s most established and influential exhibitions in the pharmaceutical manufacturing industry, API China has spent more than five decades witnessing and promote the growth of China’s pharmaceutical sector. This year’s exhibition featured tens of thousands of products spanning APIs, intermediates, pharmaceutical excipients, packaging materials, and manufacturing equipment. Dedicated zones for CRO/CMO services, natural extracts, import & export, veterinary APIs, and feed additives further highlighted the industry’s latest developments. More than one hundred high-level forums and multiple one-on-one procurement matchmaking sessions were also held during the event, creating an efficient platform for communication and cooperation across the pharmaceutical supply chain.

At this year’s exhibition, ECHEMI took concrete actions to help Chinese pharmaceutical companies identify practical and executable pathways into global markets. Through booth participation, co-hosting professional seminars, inviting overseas industry media for in-depth coverage, and producing exhibition tour videos for Chinese suppliers, ECHEMI focused on turning global expansion from abstract discussion into actionable business opportunities.

Visitors arriving at the ECHEMI booth came with highly specific concerns. Chinese suppliers were primarily focused on three key questions: What price can their products achieve in overseas markets? How should regulatory registrations and certifications be handled? And what are the latest market trends?

Manufacturers of biopharmaceutical APIs asked about DMF registration timelines and costs across Southeast Asian markets. Intermediate producers compared CEP certification requirements between GCC countries and the European Union to evaluate which production routes faced the lowest regulatory barriers. Other suppliers directly inquired about export trends and pricing movements for peptide APIs over the past six months.

Meanwhile, overseas buyers arrived with procurement lists in hand, seeking confirmation of China’s leading cephalosporin intermediate suppliers and the stability of their production capacity. Some requested information regarding Chinese DMF holdings and CEP certifications for specific products, while others asked ECHEMI to help connect them with Chinese manufacturers capable of consistently producing compliant batches under EU and US GMP standards.

To address these different needs, the ECHEMI team provided highly practical and detailed solutions directly at the booth.

For suppliers, the team carefully explained registration cycles using both official review timelines and actual average waiting periods. Regulatory requirements across markets were compared side-by-side, with special clauses highlighted directly from current legislation. When discussing market trends, the team utilized regional inquiry data and historical transaction price ranges accumulated through the ECHEMI platform.

For overseas buyers, ECHEMI relied on its supplier database and compliance records to identify China’s major manufacturers for target products, outlining production capacity, certification status, and export history. For inquiries that could not be matched immediately, the team recorded the requirements for targeted follow-up and supplier recommendations.

Every conversation at the booth was focused on moving pharmaceutical exports beyond broad industry discussions and into practical next steps that companies could genuinely execute.

Beyond consultations, ECHEMI’s professional media team also provided exhibition tour video production services for multiple Chinese suppliers. Traveling booth by booth, the team documented companies’ core products, manufacturing capabilities, and quality systems, then distributed the content through ECHEMI’s overseas social media network. This allowed international buyers unable to attend the exhibition in person to still gain a direct understanding of the real capabilities of Chinese suppliers.

At the same time, ECHEMI and API China 2026 jointly hosted the “2026 Overseas Pharmaceutical Market Products and Trends Seminar.” Three industry experts shared practical perspectives on product upgrading, regional market selection, and supply chain restructuring.

ECHEMI Vice President Bree Wang analyzed high-potential sectors including peptides and high-potency APIs, while outlining strategic recommendations such as strengthening DMF and CEP certifications and expanding into CDMO services.

Jurie Hwang explored South Korea’s export advantages and industrial ecosystem in biosimilars and CDMO services, while Muzzamil Shariff discussed the policy incentives within the Middle East’s USD 55 billion pharmaceutical market and the region’s ongoing transition from traditional trade toward technology transfer partnerships.

During the exhibition, ECHEMI also invited five industry media organizations from the Middle East, South Asia, and Southeast Asia to conduct on-site coverage. Over the course of three days, these media representatives repeatedly visited exhibition halls, filming production equipment, reviewing quality inspection reports, and speaking directly with company executives face-to-face.

Their reports would eventually return to their respective regional markets and reach local procurement decision-makers. For exhibitors, this kind of third-party industrial media coverage often carries greater credibility than self-promotion alone.

Over the three-day exhibition period, many of the more than one hundred companies that engaged with ECHEMI had already moved into detailed discussions regarding quotations and registration strategies. Market intelligence shared during the seminar was also gradually distributed to a broader group of suppliers focused on overseas expansion.

As the exhibition came to a close, practical cooperation was only beginning.

API China once again demonstrated the vitality of China’s pharmaceutical manufacturing industry while carrying the expectations of industrial upgrading. Through its participation in this major industry event, ECHEMI leveraged its understanding of global registration regulations, product demand trends, and market dynamics to help suppliers identify opportunities, connect with buyers, and build trust.

Every detailed question answered at the booth added another layer of practical reality to the broader narrative of China’s API export transformation.

Moving forward, ECHEMI will continue building upon its digital platform capabilities, combining professional market insight with execution-oriented services to support Chinese pharmaceutical enterprises as they steadily expand into global markets.